Novo Nordisk's AI Ambition Confronts a Harsh Pricing Reality

A major price increase for one of Novo Nordisk's key products was immediately overshadowed by a Wall Street downgrade, highlighting the intense pressure facing the Danish pharmaceutical giant. On April 15, the company raised the monthly price of its 4mg Wegovy pill from $149 to $199, a strategy aimed at boosting revenue. The very same day, analysts at BMO Capital slashed their price target for the stock from $45 to $36, maintaining a "Market Perform" rating. This stark juxtaposition underscores a core challenge: despite surging prescription volumes, the revenue mix is falling short of expectations.

The downgrade stems from a detailed analysis of prescription data. While an estimated 721,000 Wegovy pill prescriptions were written in the first quarter, approximately 450,000 were for the lowest 1.5mg dose. This starter dose generates the lowest revenue at $149 per month in direct sales. Consequently, BMO forecasts quarterly pill revenue of 881 million Danish kroner (DKK), a figure 12% below the consensus estimate of 1,001 million DKK. This "volume versus value" dilemma is a primary concern for investors as the company prepares to report Q1 earnings on May 6.

This pricing pressure arrives at a critical juncture. Novo Nordisk is bracing for a significant financial hit in 2026 as the patent for semaglutid—the active ingredient in Wegovy and Ozempic—expires in key markets like Canada, China, and India, opening the door to generic competition. Management has already guided for a 5% to 13% decline in sales and earnings for the year. This follows a stellar 2025 where the obesity care division alone generated over 75 billion DKK.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

In response to this looming "patent cliff," new CEO Mike Doustdar has made a bold strategic move. On April 14, Novo Nordisk announced a comprehensive partnership with OpenAI. The collaboration aims to leverage artificial intelligence to analyze vast biological datasets, accelerating the identification of promising new drug candidates. Pilot programs are launching immediately across research, production, and sales, with full integration of the AI tools targeted by the end of 2026. The company's upcoming Capital Markets Day on September 21 is expected to provide detailed long-term financial targets and outline the role of this AI strategy.

The market, however, remains deeply skeptical. Novo Nordisk's share price, closing at 33.48 EUR, has plummeted more than 41% over the past twelve months and trades over 23% below its 200-day moving average. A Relative Strength Index (RSI) reading of 19.5 indicates the stock is severely oversold. Undeterred, management continues a massive share buyback program. A tranche of 3.8 billion DKK runs until May 4, and by April 10, the company had already repurchased around 11 million B-shares at an average price of 257.56 DKK.

Beyond internal challenges, competitive threats are mounting. Rival Eli Lilly has partnered with Amazon Pharmacy to offer same-day delivery for its new GLP-1 drug, Foundayo. Novo Nordisk is countering with its new Wegovy pill and next-generation medications, while also securing regulatory wins. The FDA recently approved Awiqli, the first once-weekly basal insulin for type 2 diabetes, and Wegovy can now be transported at controlled temperatures for up to 48 hours in Europe.

The coming months will deliver crucial tests for the company's multi-pronged strategy. Key milestones include the mid-2026 start of Medicare Part D coverage for obesity drugs in the US, which should dramatically expand patient access, and an FDA decision on the combination drug CagriSema expected around the turn of 2026/2027. For now, Novo Nordisk is navigating a complex path where near-term pricing pressures and long-term patent risks are being met with aggressive AI investment and share repurchases, leaving investors to judge whether the response matches the scale of the challenge.

Ad

Novo Nordisk Stock: New Analysis - 15 April

Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Novo Nordisk analysis...

en | DK0062498333 | NOVO | boerse | 69161744 |